Epizyme Inc. (EPZM)

12.99
0.41 3.26
NASDAQ : Health Technology
Prev Close 12.58
Open 12.56
Day Low/High 12.52 / 13.03
52 Wk Low/High 5.14 / 18.70
Volume 485.33K
Avg Volume 777.50K
Exchange NASDAQ
Shares Outstanding 90.83M
Market Cap 1.10B
EPS -1.70
P/E Ratio N/A
Div & Yield N.A. (N.A)
Biotech String: Assessing the January Damage, Gilead's Bottoming P/E, Sarepta Panel Date?

Biotech String: Assessing the January Damage, Gilead's Bottoming P/E, Sarepta Panel Date?

Biotech news and observations to start the week.

Short Interest In Epizyme Moves 31.7% Lower

Short Interest In Epizyme Moves 31.7% Lower

The most recent short interest data has been released by the NASDAQ for the 01/15/2016 settlement date, which shows a 1,700,489 share decrease in total short interest for Epizyme Inc. , to 3,662,929, a decrease of 31.71% since 12/31/2015.

First Week of EPZM March 18th Options Trading

First Week of EPZM March 18th Options Trading

Investors in Epizyme Inc. saw new options begin trading this week, for the March 18th expiration.

Epizyme Announces Closing Of Public Offering Of Common Stock

Epizyme Announces Closing Of Public Offering Of Common Stock

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced the closing of its public offering of 15,333,334 shares of its common...

Oversold Conditions For Epizyme (EPZM)

Oversold Conditions For Epizyme (EPZM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Epizyme Announces Pricing Of Public Offering Of Common Stock

Epizyme Announces Pricing Of Public Offering Of Common Stock

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced the pricing of its public offering of 13,333,334 shares of its common stock...

Epizyme Announces Proposed Public Offering Of Common Stock

Epizyme Announces Proposed Public Offering Of Common Stock

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced that it intends to offer and sell up to $120,000,000 of shares of its...

Epizyme Announces First Patient Dosed In Global Clinical Program Evaluating Tazemetostat In Genetically Defined Solid Tumors

Epizyme Announces First Patient Dosed In Global Clinical Program Evaluating Tazemetostat In Genetically Defined Solid Tumors

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that the first patient has been dosed in the phase 2 study of tazemetostat in...

Short Interest Jumps 11.4% For EPZM

Short Interest Jumps 11.4% For EPZM

The most recent short interest data has been released by the NASDAQ for the 12/15/2015 settlement date, which shows a 619,146 share increase in total short interest for Epizyme Inc. , to 6,031,075, an increase of 11.44% since 11/30/2015.

Epizyme Announces FDA Acceptance Of Investigational New Drug Application For Tazemetostat In Diffuse Large B-cell Lymphoma

Epizyme Announces FDA Acceptance Of Investigational New Drug Application For Tazemetostat In Diffuse Large B-cell Lymphoma

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, today announced the U.

Insider Trading Alert - ABAX, EPZM And ERI Traded By Insiders

Insider Trading Alert - ABAX, EPZM And ERI Traded By Insiders

Stocks with insider trader activity include ABAX, EPZM and ERI

Epizyme Presents Updated Data From Ongoing Phase 1 Study Of Tazemetostat Showing Objective, Durable Responses In Relapsed Or Refractory Non-Hodgkin Lymphoma

Epizyme Presents Updated Data From Ongoing Phase 1 Study Of Tazemetostat Showing Objective, Durable Responses In Relapsed Or Refractory Non-Hodgkin Lymphoma

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, reported updated results from the ongoing phase 1 trial of tazemetostat (EPZ-6438),...

Epizyme, Inc. To Present At Piper Jaffray Conference On December 1, 2015

Epizyme, Inc. To Present At Piper Jaffray Conference On December 1, 2015

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, will participate in the Piper Jaffray 27 th Annual Healthcare Conference at the Lotte...

Epizyme Announces Third Quarter 2015 Financial Results And Provides Corporate Update

Epizyme Announces Third Quarter 2015 Financial Results And Provides Corporate Update

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, today reported business highlights and operating and financial results for the third quarter...

Epizyme Announces Presentations At 57th American Society Of Hematology Annual Meeting

Epizyme Announces Presentations At 57th American Society Of Hematology Annual Meeting

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that data from the ongoing phase 1 study of tazemetostat (EPZ-6438) will be...

Epizyme To Present New Scientific Data On The Role Of HMT Inhibitors In Cancer

Epizyme To Present New Scientific Data On The Role Of HMT Inhibitors In Cancer

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, will present data from 11 accepted abstracts on the role of histone methyltransferase (HMT)...

Epizyme To Report Third Quarter 2015 Financial Results And Provide Corporate Update On November 9, 2015

Epizyme To Report Third Quarter 2015 Financial Results And Provide Corporate Update On November 9, 2015

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, announced today it will host a conference call and live audio webcast on Monday, November...

Interesting EPZM Put And Call Options For May 2016

Interesting EPZM Put And Call Options For May 2016

Investors in Epizyme Inc. saw new options begin trading this week, for the May 2016 expiration.

Epizyme is Now Oversold (EPZM)

Epizyme is Now Oversold (EPZM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Epizyme (EPZM) Weak On High Volume

Epizyme (EPZM) Weak On High Volume

Trade-Ideas LLC identified Epizyme (EPZM) as a weak on high relative volume candidate

Epizyme To Present Clinical Data From Ongoing Phase 1 Dose Escalation Trial Of Tazemetostat (EPZ-6438) At The European Cancer Congress

Epizyme To Present Clinical Data From Ongoing Phase 1 Dose Escalation Trial Of Tazemetostat (EPZ-6438) At The European Cancer Congress

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that updated data from the phase 1 portion of its ongoing phase 1/2 study of...

Epizyme Announces Updated Tazemetostat Phase 1 Data Showing Clinical Activity In A Broader Range Of Adults With INI1-Negative And SMARCA4-Negative Solid Tumors

Epizyme Announces Updated Tazemetostat Phase 1 Data Showing Clinical Activity In A Broader Range Of Adults With INI1-Negative And SMARCA4-Negative Solid Tumors

Epizyme, Inc. (NASDAQ: EPZM) reported results today from the ongoing phase 1 trial of tazemetostat, its first-in-class EZH2 inhibitor.

Epizyme Breaks Above 200-Day Moving Average - Bullish for EPZM

Epizyme Breaks Above 200-Day Moving Average - Bullish for EPZM

In trading on Wednesday, shares of Epizyme Inc. crossed above their 200 day moving average of $20.07, changing hands as high as $20.24 per share.

Strong On High Volume: Epizyme (EPZM)

Strong On High Volume: Epizyme (EPZM)

Trade-Ideas LLC identified Epizyme (EPZM) as a strong on high relative volume candidate

Insider Trading Alert - SYNT, CMT And EPZM Traded By Insiders

Insider Trading Alert - SYNT, CMT And EPZM Traded By Insiders

Stocks with insider trader activity include SYNT, CMT and EPZM

EPZM Makes Bullish Cross Above Critical Moving Average

EPZM Makes Bullish Cross Above Critical Moving Average

In trading on Monday, shares of Epizyme Inc. crossed above their 200 day moving average of $20.29, changing hands as high as $21.27 per share.

Epizyme, Inc. To Present At Upcoming Events In September

Epizyme, Inc. To Present At Upcoming Events In September

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, will participate in four upcoming events in September: Citi 10 th ...

Epizyme Announces Acceptance Of Investigational New Drug Application For Tazemetostat In Patients With INI1-Negative Tumors Or Synovial Sarcoma

Epizyme Announces Acceptance Of Investigational New Drug Application For Tazemetostat In Patients With INI1-Negative Tumors Or Synovial Sarcoma

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for patients with cancer, today announced the U.

Epizyme Announces Second Quarter 2015 Financial Results And Provides Corporate Update

Epizyme Announces Second Quarter 2015 Financial Results And Provides Corporate Update

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, today reported business highlights and operating and financial results for the second quarter...

Epizyme Appoints Robert Bazemore President And Chief Executive Officer

Epizyme Appoints Robert Bazemore President And Chief Executive Officer

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical research and development company creating novel epigenetic therapeutics for cancer patients, announced today that Robert Bazemore will succeed Robert...

TheStreet Quant Rating: D (Sell)